Advances in Cancer Research (eBook, ePUB)
105,95 €
105,95 €
inkl. MwSt.
Sofort per Download lieferbar
53 °P sammeln
105,95 €
Als Download kaufen
105,95 €
inkl. MwSt.
Sofort per Download lieferbar
53 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
105,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
53 °P sammeln
Advances in Cancer Research (eBook, ePUB)
- Format: ePub
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Advances in Cancer Research, Volume 152 , the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.
Provides the latest information on cancer research | Offers outstanding and original reviews on a range of cancer research topics | Serves as an indispensable reference for researchers and students alike
- Geräte: eReader
- mit Kopierschutz
- eBook Hilfe
- Größe: 33.65MB
Andere Kunden interessierten sich auch für
- Advances in Cancer Research (eBook, ePUB)105,95 €
- Advances in Cancer Research (eBook, ePUB)105,95 €
- Louis J. CataniaThe Paradox of the Immune System (eBook, ePUB)114,95 €
- Hepatobiliary Cancers: Translational Advances and Molecular Medicine (eBook, ePUB)105,95 €
- Novel Approaches to Colorectal Cancer (eBook, ePUB)105,95 €
- Mechanisms and Therapy of Liver Cancer (eBook, ePUB)105,95 €
- Autophagy and Senescence in Cancer Therapy (eBook, ePUB)105,95 €
-
-
-
Advances in Cancer Research, Volume 152, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.
- Provides the latest information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Elsevier Science & Techn.
- Seitenzahl: 426
- Erscheinungstermin: 3. August 2021
- Englisch
- ISBN-13: 9780128241264
- Artikelnr.: 62364571
- Verlag: Elsevier Science & Techn.
- Seitenzahl: 426
- Erscheinungstermin: 3. August 2021
- Englisch
- ISBN-13: 9780128241264
- Artikelnr.: 62364571
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
1. Acetylcholinesterase and human cancers
Stephen D. Richbart, Justin C. Merritt, Nicholas A. Nolan, and Piyali Dasgupta
2. Head and neck cancer: Current challenges and future perspectives
Gh. Rasool Bhat, Rosalie G. Hyole, and Jiong Li
3. Metabolic control of cancer progression as novel targets for therapy
Sarmistha Talukdar, Luni Emdad, Rajan Gogna, Swadesh K. Das, and Paul B. Fisher
4. Targeting heat shock protein 90 for anti-cancer drug development
Anthony Aswad and Tuoen Liu
5. DNA methylation inhibitors: Retrospective and perspective view
Md Gias Uddin and Tamer E. Fandy
6. Roles of the tumor suppressor inhibitor of growth family member 4 (ING4) in cancer
Aymen Shatnawi, Dina I. Abu Rabe, and Daniel E. Frigo
7. Protein Tyrosine Phosphatases: A new paradigm in an old signaling system?
Colin L. Welsh, Preeti Pandey, and Lalima G. Ahuja
8. Cisplatin chemotherapy and renal function
Jie Zhang, Zhi-wei Ye, Kenneth D. Tew, and Danyelle M. Townsend
9. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC)
Indranil Banerjee, Paul B. Fisher, and Devanand Sarkar
10. Reductive stress in cancer
Leilei Zhang and Kenneth D. Tew
Stephen D. Richbart, Justin C. Merritt, Nicholas A. Nolan, and Piyali Dasgupta
2. Head and neck cancer: Current challenges and future perspectives
Gh. Rasool Bhat, Rosalie G. Hyole, and Jiong Li
3. Metabolic control of cancer progression as novel targets for therapy
Sarmistha Talukdar, Luni Emdad, Rajan Gogna, Swadesh K. Das, and Paul B. Fisher
4. Targeting heat shock protein 90 for anti-cancer drug development
Anthony Aswad and Tuoen Liu
5. DNA methylation inhibitors: Retrospective and perspective view
Md Gias Uddin and Tamer E. Fandy
6. Roles of the tumor suppressor inhibitor of growth family member 4 (ING4) in cancer
Aymen Shatnawi, Dina I. Abu Rabe, and Daniel E. Frigo
7. Protein Tyrosine Phosphatases: A new paradigm in an old signaling system?
Colin L. Welsh, Preeti Pandey, and Lalima G. Ahuja
8. Cisplatin chemotherapy and renal function
Jie Zhang, Zhi-wei Ye, Kenneth D. Tew, and Danyelle M. Townsend
9. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC)
Indranil Banerjee, Paul B. Fisher, and Devanand Sarkar
10. Reductive stress in cancer
Leilei Zhang and Kenneth D. Tew
1. Acetylcholinesterase and human cancers
Stephen D. Richbart, Justin C. Merritt, Nicholas A. Nolan, and Piyali Dasgupta
2. Head and neck cancer: Current challenges and future perspectives
Gh. Rasool Bhat, Rosalie G. Hyole, and Jiong Li
3. Metabolic control of cancer progression as novel targets for therapy
Sarmistha Talukdar, Luni Emdad, Rajan Gogna, Swadesh K. Das, and Paul B. Fisher
4. Targeting heat shock protein 90 for anti-cancer drug development
Anthony Aswad and Tuoen Liu
5. DNA methylation inhibitors: Retrospective and perspective view
Md Gias Uddin and Tamer E. Fandy
6. Roles of the tumor suppressor inhibitor of growth family member 4 (ING4) in cancer
Aymen Shatnawi, Dina I. Abu Rabe, and Daniel E. Frigo
7. Protein Tyrosine Phosphatases: A new paradigm in an old signaling system?
Colin L. Welsh, Preeti Pandey, and Lalima G. Ahuja
8. Cisplatin chemotherapy and renal function
Jie Zhang, Zhi-wei Ye, Kenneth D. Tew, and Danyelle M. Townsend
9. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC)
Indranil Banerjee, Paul B. Fisher, and Devanand Sarkar
10. Reductive stress in cancer
Leilei Zhang and Kenneth D. Tew
Stephen D. Richbart, Justin C. Merritt, Nicholas A. Nolan, and Piyali Dasgupta
2. Head and neck cancer: Current challenges and future perspectives
Gh. Rasool Bhat, Rosalie G. Hyole, and Jiong Li
3. Metabolic control of cancer progression as novel targets for therapy
Sarmistha Talukdar, Luni Emdad, Rajan Gogna, Swadesh K. Das, and Paul B. Fisher
4. Targeting heat shock protein 90 for anti-cancer drug development
Anthony Aswad and Tuoen Liu
5. DNA methylation inhibitors: Retrospective and perspective view
Md Gias Uddin and Tamer E. Fandy
6. Roles of the tumor suppressor inhibitor of growth family member 4 (ING4) in cancer
Aymen Shatnawi, Dina I. Abu Rabe, and Daniel E. Frigo
7. Protein Tyrosine Phosphatases: A new paradigm in an old signaling system?
Colin L. Welsh, Preeti Pandey, and Lalima G. Ahuja
8. Cisplatin chemotherapy and renal function
Jie Zhang, Zhi-wei Ye, Kenneth D. Tew, and Danyelle M. Townsend
9. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC)
Indranil Banerjee, Paul B. Fisher, and Devanand Sarkar
10. Reductive stress in cancer
Leilei Zhang and Kenneth D. Tew